In context
Enfuvirtide is an antiviral peptide medicine used in a defined HIV treatment context. [1–2]
At a glance
- Type
- Medicine / medicine family
- Regulatory context
- Historical US label. FDA announced withdrawal of approval for Fuzeon effective 5 August 2026.
- Evidence
- The cited product label defines a clinical indication and its limits. It does not validate every formulation or use of a related molecule.
Scope of the labelled use
It belongs in specialist combination antiretroviral care. Its mechanism is not evidence for general immune enhancement. [1]
Reading a historical label
The cited label records a historical indication. It is not confirmation of current approval or supply, and must not be used as current prescribing guidance. [1]
Safety and clinical context
The full prescribing information includes product-specific warnings, contraindications and monitoring requirements. A clinical assessment must consider these alongside other medicines and individual health conditions.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- Fuzeon prescribing information (2019; historical label) www.accessdata.fda.gov
- FDA withdrawal notice — Federal Register, 6 July 2026 www.govinfo.gov